Liposomal voriconazole (VOR) formulation for improved ocular delivery

Sá, Fernando Augusto Pires de; Taveira, Stephânia Fleury; Gelfuso, Guilherme M.; Lima, Eliana Martins; Gratieri, Taís

doi:10.1016/j.colsurfb.2015.06.036

Cited by 88 publications

(37 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical VRC can penetrate the cornea, and therapeutic concentration can be achieved in the cornea, aqueous humor and vitreous body [8, 9]. To date, no topical formulation for ocular use has become commercially available, although several attempts involving cyclodextrin based eye drop solutions and gels [10, 11], microemulsions [12], liposomes [13], and niosomes [14] have revealed the potential of VRC for topical ophthalmic administration.…”

Section: Introductionmentioning

confidence: 99%

Voriconazole Composited Polyvinyl Alcohol/Hydroxypropyl-β-Cyclodextrin Nanofibers for Ophthalmic Delivery

Sun

Cai

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Voriconazole (VRC) incorporated in composited polyvinyl alcohol (PVA)/hydroxypropyl-β-cyclodextrin (HPβCD) blended nanofibers were produced via electrospinning for efficient ophthalmic delivery. The VRC loading capacity increased with increasing HPβCD content. The optimal solution for electrospinning consisted of 8% (w/v) PVA, 4% (w/v) HPβCD and 0.5% (w/v) VRC. The nanofibers exhibited bead-free average fiber diameters of 307±31 nm and VRC was released in vitro in a sustained manner. The VRC nanofibers were characterized by infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and scanning electron microscopy (SEM). The proton nuclear magnetic resonance (1H-NMR) was used to analyze the molar ratio of HPβCD/VRC in the nanofibers. Compared with a VRC solution, the nanofibers significantly prolonged the half life, and increased the bioavailability of VRC in rabbit tears. No obvious signs of irritation were observed after application in the conjunctival sac. VRC nanofibers are promising for ophthalmic drug delivery and further pharmacodynamics studies are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Voriconazole Composited Polyvinyl Alcohol/Hydroxypropyl-β-Cyclodextrin Nanofibers for Ophthalmic Delivery

Sun

Cai

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Additional formulations are currently being investigated worldwide, including a sustained release tablet for IFI [41], liposomal [42] and nanostructured lipid [43] formulations intended for ocular delivery , and an inhaled dry powder formulation of voriconazole that would allow more direct treatment of invasive pulmonary aspergillosis although no human safety or efficacy data is available at this time [44][45][46].…”

Section: Voriconazole Formulationsmentioning

confidence: 98%

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections

Job

Olson

Constance

et al. 2016

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

The objective of this review is to summarize the pharmacodynamic properties of voriconazole and to provide considerations for potential optimal dosing strategies. Studies have demonstrated superior clinical response when an AUC/MIC >25 or Cmin/MIC >1 is attained in adult patients, correlating to a trough concentration range as narrow as 2-4.5 mg/L; however, these targets are poorly established in the pediatric population. Topics in this discussion include voriconazole use in multiple age groups, predisposing patient factors for IFI, and considerations for clinicians managing IFI. Expert commentary: The relationship between voriconazole dosing and exposure is not well defined due to the large inter- and intra-subject variability. Development of comprehensive decision support tools for individualizing dosing, particularly in children who require higher dosing, will help to increase the probability of achieving therapeutic efficacy and decrease sub-therapeutic dosing and adverse events.

show abstract

“…Equal volumes of each prepared hydrogel, one at a time, and the 1% (w/v) mucin particles solution were mixed using a vortex for 1 min. The zeta potential of each of the mucin solution and the mixtures was measured using Zetasizer and the changes in the zeta potential following interaction of the hydrogel with the negatively charged mucin [27] was investigated.…”

Section: Mucoadhesion Evaluationmentioning

confidence: 99%

Plga Nanoparticles Loaded Mucoadhesive and Thermosensitive Hydrogel as a Potential Platform for the Treatment of Oral Mucositis

El-Feky¹,

Zayed

2019

Int J App Pharm

View full text Add to dashboard Cite

Objective: The objective of this study was to design an effective topical treatment for oral mucositis.Methods: Poly-(DL-lactide-co-glycolide) (PLGA) nanoparticles (NPs) and Poloxamer407 (PLX)/Hydroxy propyl methyl cellulose (HPMC) hydrogel matrix (HG) were used as combined carriers for benzydamine HCL (BNZ). BNZ loaded PLGA nanoparticles were assessed for their particle size, PDI, zeta potential and entrapment efficiency. Scanning electron microscopy, thermosensitivity study, mucoadhesion study, in vitro release and in vivo investigation were used to characterize the combined BZN loaded PLGA NPs HG.Results: Negatively charged NPs with an average diameter of 139±4.92 nm were incorporated into PLX/HPMC HG bases. The gelation temperature of BZN-PLGA-NPs-HGs ranged between 31°C and 36.5°C. When diluted with saliva simulated fluid, BZN-PLGA-NPs-HGs preserved their gelation properties. Mucoadhesion was found lower for formulations prepared with PLX without HPMC. An increase in the concentrations of PLX from 10 to 30% resulted in an increase in adhesion. Both PLGA-NPs and PLGA-NPs-HG provided a biphasic drug release profile while BZN-HG provided monophasic zero order release pattern. The in vivo study showed that animal groups treated with BZN-HG and BZN-PLGA-NPs-HG showed a significantly higher reduction percentage in ulcer surface area compared to those treated with BZN-PLGA-NPs. BZN-PLGA-NPs-HG group needed 10 d of treatment to complete healing versus 16 d, 14 d and 12 d for the complete healing of groups with no treatment, treated with BZN-PLGA-NPs and treated with BZN-HG, respectively.Conclusion: BZN-PLGA-NPs-HG could represent a promising mean for the effective treatment of oral mucositis induced by cancer therapy.

show abstract

Liposomal voriconazole (VOR) formulation for improved ocular delivery

Cited by 88 publications

References 39 publications

Voriconazole Composited Polyvinyl Alcohol/Hydroxypropyl-β-Cyclodextrin Nanofibers for Ophthalmic Delivery

Voriconazole Composited Polyvinyl Alcohol/Hydroxypropyl-β-Cyclodextrin Nanofibers for Ophthalmic Delivery

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections

Plga Nanoparticles Loaded Mucoadhesive and Thermosensitive Hydrogel as a Potential Platform for the Treatment of Oral Mucositis

Contact Info

Product

Resources

About